Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.38
AKRX's Cash-to-Debt is ranked lower than
75% of the 886 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. AKRX: 0.38 )
Ranked among companies with meaningful Cash-to-Debt only.
AKRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.31 Max: No Debt
Current: 0.38
0
No Debt
Equity-to-Asset 0.44
AKRX's Equity-to-Asset is ranked lower than
75% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. AKRX: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
AKRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.53 Max: 0.95
Current: 0.44
0.1
0.95
Debt-to-Equity 1.01
AKRX's Debt-to-Equity is ranked lower than
85% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. AKRX: 1.01 )
Ranked among companies with meaningful Debt-to-Equity only.
AKRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.51 Max: 7.46
Current: 1.01
0.01
7.46
Debt-to-EBITDA -21.53
AKRX's Debt-to-EBITDA is ranked lower than
98% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. AKRX: -21.53 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AKRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -21.53  Med: 1.65 Max: 12.73
Current: -21.53
-21.53
12.73
Piotroski F-Score: 4
Altman Z-Score: 1.89
Beneish M-Score: -2.93
WACC vs ROIC
9.90%
-1.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % -3.19
AKRX's Operating Margin % is ranked lower than
74% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.96 vs. AKRX: -3.19 )
Ranked among companies with meaningful Operating Margin % only.
AKRX' s Operating Margin % Range Over the Past 10 Years
Min: -25.71  Med: 20.86 Max: 33.18
Current: -3.19
-25.71
33.18
Net Margin % -12.22
AKRX's Net Margin % is ranked lower than
74% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. AKRX: -12.22 )
Ranked among companies with meaningful Net Margin % only.
AKRX' s Net Margin % Range Over the Past 10 Years
Min: -33.35  Med: 14.56 Max: 31.41
Current: -12.22
-33.35
31.41
ROE % -11.01
AKRX's ROE % is ranked lower than
70% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.75 vs. AKRX: -11.01 )
Ranked among companies with meaningful ROE % only.
AKRX' s ROE % Range Over the Past 10 Years
Min: -50.57  Med: 21.2 Max: 35.12
Current: -11.01
-50.57
35.12
ROA % -4.79
AKRX's ROA % is ranked lower than
68% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.29 vs. AKRX: -4.79 )
Ranked among companies with meaningful ROA % only.
AKRX' s ROA % Range Over the Past 10 Years
Min: -33.5  Med: 8.42 Max: 24.27
Current: -4.79
-33.5
24.27
ROC (Joel Greenblatt) % -23.20
AKRX's ROC (Joel Greenblatt) % is ranked lower than
72% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.64 vs. AKRX: -23.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AKRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -48.96  Med: 56.56 Max: 74.87
Current: -23.2
-48.96
74.87
3-Year Revenue Growth Rate 10.00
AKRX's 3-Year Revenue Growth Rate is ranked higher than
66% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. AKRX: 10.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AKRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -37.1  Med: 10.2 Max: 56.6
Current: 10
-37.1
56.6
3-Year EBITDA Growth Rate -22.10
AKRX's 3-Year EBITDA Growth Rate is ranked lower than
95% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.90 vs. AKRX: -22.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AKRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -43.2 Max: 132.1
Current: -22.1
0
132.1
GuruFocus has detected 3 Warning Signs with Akorn Inc AKRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AKRX's 30-Y Financials

Financials (Next Earnings Date: 2018-07-31)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

AKRX Guru Trades in Q2 2017

Jim Simons 909,904 sh (New)
Paul Tudor Jones 375,000 sh (+4364.29%)
Mario Gabelli 276,825 sh (+323.93%)
Joel Greenblatt 218,027 sh (+256.06%)
First Pacific Advisors Sold Out
John Paulson Sold Out
David Dreman Sold Out
FPA Capital Fund Sold Out
Richard Snow Sold Out
Columbia Wanger Sold Out
Robert Olstein Sold Out
Murray Stahl 11,935 sh (-34.31%)
Lee Ainslie 71,220 sh (-45.95%)
» More
Q3 2017

AKRX Guru Trades in Q3 2017

Jim Simons 2,693,500 sh (+196.02%)
Lee Ainslie 104,180 sh (+46.28%)
Paul Tudor Jones Sold Out
Murray Stahl 11,869 sh (-0.55%)
Mario Gabelli 274,235 sh (-0.94%)
Joel Greenblatt 95,226 sh (-56.32%)
» More
Q4 2017

AKRX Guru Trades in Q4 2017

Lee Ainslie 216,280 sh (+107.60%)
Jim Simons 2,832,600 sh (+5.16%)
Murray Stahl Sold Out
Mario Gabelli 246,435 sh (-10.14%)
Joel Greenblatt 25,332 sh (-73.40%)
» More
Q1 2018

AKRX Guru Trades in Q1 2018

Chuck Royce 689 sh (New)
Lee Ainslie 610,460 sh (+182.25%)
Joel Greenblatt Sold Out
Mario Gabelli 213,035 sh (-13.55%)
Jim Simons 1,193,100 sh (-57.88%)
» More
» Details

Insider Trades

Latest Guru Trades with AKRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2018-03-31 Reduce -13.55%0.01%$16.94 - $33.56 $ 16.03-41%213,035
Joel Greenblatt 2018-03-31 Sold Out 0.01%$16.94 - $33.56 $ 16.03-41%0
Mario Gabelli 2017-12-31 Reduce -10.14%0.01%$31.84 - $33.48 $ 16.03-51%246,435
Joel Greenblatt 2017-12-31 Reduce -73.40%0.04%$31.84 - $33.48 $ 16.03-51%25,332
Mario Gabelli 2017-09-30 Reduce -0.94%$31.98 - $33.7 $ 16.03-52%274,235
Joel Greenblatt 2017-09-30 Reduce -56.32%0.06%$31.98 - $33.7 $ 16.03-52%95,226
Mario Gabelli 2017-06-30 Add 323.93%0.05%$23.33 - $33.58 $ 16.03-51%276,825
Joel Greenblatt 2017-06-30 Add 256.06%0.07%$23.33 - $33.58 $ 16.03-51%218,027
John Paulson 2017-06-30 Sold Out 2.7%$23.33 - $33.58 $ 16.03-51%0
Robert Olstein 2017-06-30 Sold Out 0.71%$23.33 - $33.58 $ 16.03-51%0
FPA Capital Fund 2017-06-30 Sold Out 1.83%$23.33 - $33.58 $ 16.03-51%0
David Dreman 2017-06-30 Sold Out 0.25%$23.33 - $33.58 $ 16.03-51%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:SHSE:603567, SZSE:300630, TSE:4555, NAS:OPK, NAS:PAHC, XKRX:145020, HKSE:02877, TSE:8129, NYSE:DPLO, XKRX:041960, SHSE:600781, NAS:MNTA, BOM:540596, SZSE:002737, BOM:532872, SHSE:603367, SHSE:600329, TSX:LEAF, SZSE:300401, BOM:533573 » details
Traded in other countries:FDA.Germany,
Headquarter Location:USA
Akorn Inc is a United States based generic pharmaceutical company. It develops, manufactures and markets generic and branded prescription pharmaceuticals as well as private-label over-the-counter consumer health products and animal health pharmaceuticals.

Akorn manufactures ophthalmology and dermatology products as well as injectables. In ophthalmology, the firm primarily sells generic and over-the-counter products but has a small branded portfolio that was purchased from Merck. The firm is primarily focused on the United States.

Top Ranked Articles about Akorn Inc

Lawsuit for Investors in shares of Akorn, Inc. (NASDAQ: AKRX) announced by Shareholders Foundation
Moore Kuehn, PLLC Announces an Investigation Involving Possible Breaches of Fiduciary Duties by Officers and Directors of Akorn, Inc.
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Akorn, Inc. (Nasdaq: AKRX) To Contact The Firm
Rosen Law Firm Reminds Akorn, Inc. Investors of Important May 7 Deadline in Class Action – AKRX
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018
Lifshitz & Miller LLP Announces Investigation of Acadia Healthcare Company, Inc., Akorn, Inc., Blackhawk Network Holdings, Inc., Facebook, Inc., IZEA Inc., MuleSoft, Inc., Solid Biosciences Inc., and Tableau Software, Inc.
AKORN, INC. INVESTOR ALERT:  Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of Illinois on behalf of shareholders of Akorn, I
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (AKRX)
Should you buy or sell Akorn Inc., Google, Halliburton, Hasbro and Verizon Communications?
Analysis: Positioning to Benefit within Team, Fortinet, Rockwell Collins, Franklin Street Properties, Akorn, and Targa Resources — Research Highlights Growth, Revenue, and Consolidated Results

Ratios

vs
industry
vs
history
Forward PE Ratio 24.27
AKRX's Forward PE Ratio is ranked lower than
59% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.00 vs. AKRX: 24.27 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.47
AKRX's PB Ratio is ranked higher than
51% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. AKRX: 2.47 )
Ranked among companies with meaningful PB Ratio only.
AKRX' s PB Ratio Range Over the Past 10 Years
Min: 1.42  Med: 6.02 Max: 16.87
Current: 2.47
1.42
16.87
PS Ratio 2.59
AKRX's PS Ratio is ranked higher than
54% of the 784 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. AKRX: 2.59 )
Ranked among companies with meaningful PS Ratio only.
AKRX' s PS Ratio Range Over the Past 10 Years
Min: 0.75  Med: 5.71 Max: 12.98
Current: 2.59
0.75
12.98
Price-to-Operating-Cash-Flow 21.99
AKRX's Price-to-Operating-Cash-Flow is ranked higher than
82% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.21 vs. AKRX: 21.99 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AKRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.08  Med: 43.58 Max: 192.86
Current: 21.99
9.08
192.86
EV-to-EBIT -20.52
AKRX's EV-to-EBIT is ranked lower than
99.99% of the 599 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.78 vs. AKRX: -20.52 )
Ranked among companies with meaningful EV-to-EBIT only.
AKRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -219.8  Med: 16.8 Max: 213.1
Current: -20.52
-219.8
213.1
EV-to-EBITDA -66.31
AKRX's EV-to-EBITDA is ranked lower than
93% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.59 vs. AKRX: -66.31 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -93.5  Med: 15.5 Max: 2955.7
Current: -66.31
-93.5
2955.7
EV-to-Revenue 3.25
AKRX's EV-to-Revenue is ranked lower than
51% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. AKRX: 3.25 )
Ranked among companies with meaningful EV-to-Revenue only.
AKRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 6 Max: 14.8
Current: 3.25
0.8
14.8
Shiller PE Ratio 42.91
AKRX's Shiller PE Ratio is ranked lower than
67% of the 230 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.11 vs. AKRX: 42.91 )
Ranked among companies with meaningful Shiller PE Ratio only.
AKRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 31.73  Med: 86.75 Max: 2690.5
Current: 42.91
31.73
2690.5
Current Ratio 4.64
AKRX's Current Ratio is ranked higher than
70% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. AKRX: 4.64 )
Ranked among companies with meaningful Current Ratio only.
AKRX' s Current Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.44 Max: 17
Current: 4.64
0.21
17
Quick Ratio 3.37
AKRX's Quick Ratio is ranked higher than
65% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.02 vs. AKRX: 3.37 )
Ranked among companies with meaningful Quick Ratio only.
AKRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.41 Max: 12.29
Current: 3.37
0.02
12.29
Days Inventory 164.37
AKRX's Days Inventory is ranked lower than
71% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.78 vs. AKRX: 164.37 )
Ranked among companies with meaningful Days Inventory only.
AKRX' s Days Inventory Range Over the Past 10 Years
Min: 118.8  Med: 148.93 Max: 173.39
Current: 164.37
118.8
173.39
Days Sales Outstanding 83.74
AKRX's Days Sales Outstanding is ranked higher than
64% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.10 vs. AKRX: 83.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.46  Med: 64.41 Max: 123.33
Current: 83.74
25.46
123.33
Days Payable 54.32
AKRX's Days Payable is ranked lower than
73% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. AKRX: 54.32 )
Ranked among companies with meaningful Days Payable only.
AKRX' s Days Payable Range Over the Past 10 Years
Min: 19.92  Med: 48.51 Max: 113.99
Current: 54.32
19.92
113.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.80
AKRX's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. AKRX: -3.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AKRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -63.1  Med: -4.6 Max: -0.3
Current: -3.8
-63.1
-0.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.05
AKRX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. AKRX: 1.05 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AKRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.02  Med: 6.03 Max: 749
Current: 1.05
1.02
749
Price-to-Median-PS-Value 0.46
AKRX's Price-to-Median-PS-Value is ranked higher than
92% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. AKRX: 0.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AKRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.2 Max: 2.12
Current: 0.46
0.04
2.12
Earnings Yield (Greenblatt) % -4.90
AKRX's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. AKRX: -4.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.6  Med: 2.9 Max: 10.7
Current: -4.9
-19.6
10.7
Forward Rate of Return (Yacktman) % 25.29
AKRX's Forward Rate of Return (Yacktman) % is ranked higher than
96% of the 414 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.53 vs. AKRX: 25.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AKRX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.5  Med: -0.3 Max: 25.29
Current: 25.29
-15.5
25.29

More Statistics

Revenue (TTM) (Mil) $771.69
EPS (TTM) $ -0.76
Beta1.66
Volatility52.61%
52-Week Range $10.76 - 33.73
Shares Outstanding (Mil)125.26

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 748 763 773
EBIT (Mil $) 40 69
EBITDA (Mil $) 142 157 172
EPS ($) 0.05 0.16 0.24
EPS without NRI ($) 0.05 0.16 0.24
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-7.22%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}